Current performance standards are high and promising new technologies are finding it difficult to compete
The narrative review in this issue of the MJA by Chen and Jepson1 outlines the enormous advances made in stent technology since Sigwart and colleagues published the first report on the clinical use of coronary stents in 1987.2 Driven by technological progress and rigorous scientific study, coronary stents have advanced rapidly to the stage where a patient’s coronary stenosis can be safely and reliably opened.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Chen D, Jepson N. Coronary stent technology: a narrative review. Med J Aust 2016; 205: 277-281.
- 2. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and re-stenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701-706.
- 3. Gada H, Kirtane AJ, Newman W, et al. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions. JACC Cardiovasc Interv 2013; 6: 1263-1266.
- 4. Räber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer generation everolimus-eluting stent compared with early generation drug-eluting stents: a prospective cohort study. Circulation 2012; 125: 1110-1121.
- 5. Kirtane AJ, Leon MB, Ball MW, et al. The “final” 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv 2013; 6: 325-333.
- 6. Taniwaki M, Stefanini GG, Silber S, et al. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE all-comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent. J Am Coll Cardiol 2014; 63: 1617-1625.
- 7. Valgimigli M, Gagnor A, Calabró P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet 2015; 6736: 1-12.
- 8. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516.
- 9. Généreux P, Kumsars I, Lesiak M, et al. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. J Am Coll Cardiol 2015; 65: 533-543.
No relevant disclosures.